Arovella Therapeutics signs global, exclusive licence agreement for solid tumour targeting technology

Following the completion of all preclinical proof-of-concept, safety and specificity studies and toxicology studies required to commence a Phase 1 trial to...

Related Keywords

,Astellas Pharma ,Michael Baker ,Dong Zhu ,Ganymed Pharmaceuticals ,Sparx Group ,Drug Administration ,Arovella Therapeutics Ltd ,Priority Review ,Addressing Critical Cancer ,Gui Dong Zhu ,